We are live on ! Find out more
BC

Broadwood Capital Portfolio holdings

AUM $1.42B
1-Year Est. Return 34.72%
This Fund
S&P 500
This Quarter Est. Return
+6.52%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$517M
AUM Growth
+$34.8M
Cap. Flow
+$18.1M
Cap. Flow %
3.5%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
3
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
LCTX icon
Lineage Cell Therapeutics
LCTX
+$7.66M
2
AST
Asterias Biotherapeutics Inc. Series A
AST
+$7.44M
3
STAA icon
STAAR Surgical
STAA
+$2.83M
4
AST.WS
Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
+$171K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Consumer Staples 49.67%
2 Healthcare 30.37%
3 Technology 2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNST icon
1
Monster Beverage
MNST
$94.3B
$257M 49.67%
9,594,816
– –
LCTX icon
2
Lineage Cell Therapeutics
LCTX
$269M
$65M 12.56%
28,457,308
+3,123,403
+12% +$7.66M
STAA icon
3
STAAR Surgical
STAA
$1.21B
$59.8M 11.56%
10,855,179
+437,509
+4% +$2.83M
IWM icon
4
iShares Russell 2000 ETF
IWM
$79.8B
$48.3M 9.33%
420,000
– –
CYNO
5
DELISTED
Cynosure, Inc. Class A
CYNO
$44.6M 8.62%
916,975
– –
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$19.6M 3.79%
322,411
– –
IMPR
7
DELISTED
IMPRIVATA, INC COM
IMPR
$10.3M 2%
737,911
– –
AST
8
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$8.88M 1.72%
3,699,848
+2,058,823
+125% +$7.44M
IMDX
9
Insight Molecular Diagnostics
IMDX
$150M
$3.89M 0.75%
54,661
– –
AST.WS
10
DELISTED
Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
$70K 0.01%
+328,205
New +$171K

Similar funds

PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
EWS
Evergreen Wealth Solutions Williamsport, Pennsylvania $1.41B AUM 18.71% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
PPC
Park Presidio Capital San Francisco, California $1.43B AUM 21.33% 1-Year Est. Return

Broadwood Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Broadwood Capital held 10 positions worth $517M, up 7.2% from $483M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Broadwood Capital deployed $18.1M of net new capital in Q2 2016, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017): 328,205 shares worth $70K.

By sector, the portfolio is most concentrated in Consumer Staples at 50% of assets, up from 44% a quarter earlier, followed by Healthcare and Technology.

  • Broadwood Capital's largest Q2 2016 buy was Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017): 328,205 shares worth $70K.
  • Broadwood Capital added most to Lineage Cell Therapeutics in Q2 2016, an estimated $7.66M increase.
  • Broadwood Capital's ten largest holdings make up 100% of its $517M portfolio in Q2 2016.
  • Broadwood Capital opened 1 new position and closed 0 in Q2 2016.
  • Broadwood Capital's portfolio value rose 7.2% quarter-over-quarter to $517M.

Based on Broadwood Capital's 13F filing for Q2 2016, filed 15 Aug 2016.